Ernexa Therapeutics (ERNAW) Accumulated Depreciation (2012 - 2025)

Ernexa Therapeutics (ERNAW) has 11 years of Accumulated Depreciation data on file, last reported at $197000.0 in Q4 2025.

• Quarterly Accumulated Depreciation rose 14.53% year-over-year to $197000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $197000.0 (up 14.53% YoY) and the FY2025 annual result came in at $197000.0, up 14.53% from the prior year.
• Accumulated Depreciation improved to $197000.0 in Q4 2025, from $172000.0 in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $207000.0 in Q4 2021 to a low of $32000.0 in Q4 2022.
• A 5-year average of $144566.7 and a median of $158700.0 in 2021 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation plunged 84.54% — and 2023, when it jumped 256.25%.
• Tracing ERNAW's Accumulated Depreciation over 5 years: stood at $207000.0 in 2021, then sank by 84.54% to $32000.0 in 2022, then jumped by 256.25% to $114000.0 in 2023, then soared by 50.88% to $172000.0 in 2024, then rose by 14.53% to $197000.0 in 2025.
• The last three Accumulated Depreciation figures came in at $197000.0 (Q4 2025), $172000.0 (Q4 2024), and $114000.0 (Q4 2023), per Business Quant data.